ARMATA PHARMACEUTICALS, INC. Impairment of Long-Lived Assets Held-for-use
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-03-21
- ARMATA PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00.
- ARMATA PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- ARMATA PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- ARMATA PHARMACEUTICALS, INC. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month | Impairment of Long-Lived Assets Held-for-use 24 month |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-21 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-21 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-21 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | |
| 2020-12-31 | $0.00 10-K · filed 2021-03-18 | |
| 2019-12-31 | $0.00 10-K · filed 2020-03-19 | |
| 2017-12-31 | $0.00 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |